Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China
AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal calprotectin(FC), clinical activity index(CDAI or CAI), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), and procalcitonin(PCT) were measured fo...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 23; no. 46; pp. 8235 - 8247 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Inc
14.12.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal calprotectin(FC), clinical activity index(CDAI or CAI), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), and procalcitonin(PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome(IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn’s disease(CICD) with the “simple endoscopic score for Crohn’s disease”(SES-CD), CDrelated surgery patients with the Rutgeerts score, and ulcerative colitis(UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ~2 test, Spearman’s correlation, and multiple linear regression analysis.RESULTS The median FC levels in CD, UC, and IBS patients were 449.6(IQR, 137.9-1344.8), 497.9(IQR, 131.7-118.0), and 9.9(IQR, 0-49.7) μg/g, respectively(P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC(r = 0.802), followed by CDAI(r = 0.734), CRP(r = 0.658), and ESR(r = 0.557). The Mayo score also correlated significantly with FC(r = 0.837), CAI(r = 0.776), ESR(r = 0.644), and CRP(r = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity(CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve(AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC(0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients. CONCLUSION FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation. |
---|---|
AbstractList | To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD).
Fecal calprotectin (FC), clinical activity index (CDAI or CAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome (IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn's disease (CICD) with the "simple endoscopic score for Crohn's disease" (SES-CD), CD-related surgery patients with the Rutgeerts score, and ulcerative colitis (UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ
test, Spearman's correlation, and multiple linear regression analysis.
The median FC levels in CD, UC, and IBS patients were 449.6 (IQR, 137.9-1344.8), 497.9 (IQR, 131.7-118.0), and 9.9 (IQR, 049.7) μg/g, respectively (P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC (
= 0.802), followed by CDAI (
= 0.734), CRP (
= 0.658), and ESR (
= 0.557). The Mayo score also correlated significantly with FC (
= 0.837), CAI (r = 0.776), ESR (
= 0.644), and CRP (
= 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity (CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve (AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC (0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients.
FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation. AIMTo optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD).METHODSFecal calprotectin (FC), clinical activity index (CDAI or CAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome (IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn's disease (CICD) with the "simple endoscopic score for Crohn's disease" (SES-CD), CD-related surgery patients with the Rutgeerts score, and ulcerative colitis (UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ2 test, Spearman's correlation, and multiple linear regression analysis.RESULTSThe median FC levels in CD, UC, and IBS patients were 449.6 (IQR, 137.9-1344.8), 497.9 (IQR, 131.7-118.0), and 9.9 (IQR, 049.7) μg/g, respectively (P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC (r = 0.802), followed by CDAI (r = 0.734), CRP (r = 0.658), and ESR (r = 0.557). The Mayo score also correlated significantly with FC (r = 0.837), CAI (r = 0.776), ESR (r = 0.644), and CRP (r = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity (CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve (AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC (0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients.CONCLUSIONFC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation. AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal calprotectin(FC), clinical activity index(CDAI or CAI), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), and procalcitonin(PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome(IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn’s disease(CICD) with the “simple endoscopic score for Crohn’s disease”(SES-CD), CDrelated surgery patients with the Rutgeerts score, and ulcerative colitis(UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ~2 test, Spearman’s correlation, and multiple linear regression analysis.RESULTS The median FC levels in CD, UC, and IBS patients were 449.6(IQR, 137.9-1344.8), 497.9(IQR, 131.7-118.0), and 9.9(IQR, 0-49.7) μg/g, respectively(P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC(r = 0.802), followed by CDAI(r = 0.734), CRP(r = 0.658), and ESR(r = 0.557). The Mayo score also correlated significantly with FC(r = 0.837), CAI(r = 0.776), ESR(r = 0.644), and CRP(r = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity(CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve(AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC(0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients. CONCLUSION FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation. |
Author | Jin-Min Chen Tao Liu Shan Gao Xu-Dong Tong Fei-Hong Deng Biao Nie |
AuthorAffiliation | Department of Gastroenterology,Xiangyang Central Hospital,Hubei University of Arts and Science;Department of Gastroenterology,the Sixth Affiliated Hospital of Sun Yat-sen University;Guangdong Provincial Key Laboratory of Gastroenterology,Department of Gastroenterology,Nanfang Hospital,Southern Medical University;Department of Gastroenterology,the First Affiliated Hospital of Jinan University,Jinan University |
Author_xml | – sequence: 1 givenname: Jin-Min surname: Chen fullname: Chen, Jin-Min organization: Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China – sequence: 2 givenname: Tao surname: Liu fullname: Liu, Tao organization: Department of Gastroenterology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510665, Guangdong Province, China – sequence: 3 givenname: Shan surname: Gao fullname: Gao, Shan organization: Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China – sequence: 4 givenname: Xu-Dong surname: Tong fullname: Tong, Xu-Dong organization: Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China – sequence: 5 givenname: Fei-Hong surname: Deng fullname: Deng, Fei-Hong organization: Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China – sequence: 6 givenname: Biao surname: Nie fullname: Nie, Biao email: niebiao2@163.com organization: Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, Guangzhou 510630, Guangdong Province, China. niebiao2@163.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29290660$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkUFv1DAQhS1URLcLd07IRy5ZxnacxByQ0KrQSpW4wNmaJPauq8Texkmq_HscuqzAF3s8b549892QKx-8IeQ9g50o8-rT8-NhN3Oxc3mxq7iQr8iGc6YyXuVwRTYMoMyU4OU1uYnxEYALIfkbcs0VV1AUsCHx1lrXYLPQYGlyd37G6GZDzYzdhKMLPlLnaZ9SYxicP6TIdtj3mMKF1uHZdLR10WA0FJvRzW5cPlOkpyHEk1kvDI3j1C6rzf7oPL4lry120bw771vy69vtz_1d9vDj-_3-60PWSCjGTLQSG14bVRvGoagBcistly1wLqC2rcWaCdZUDIWpTdlKKYq6VMhKCTwvxZZ8efE9TXVv2sb4ccBOnwbX47DogE7_n_HuqA9h1rIUSglIBh_PBkN4mkwcde9iY7oOvQlT1ExVgsuCJfGWwIu0SW3HwdjLMwz0ykonVjqx0omVXlmlkg__fu9S8BdOEoiz5zH4w1Oa_UWjoFqXkpBXuZJScpn_OXHxG31lpd4 |
CitedBy_id | crossref_primary_10_1016_j_mri_2024_06_001 crossref_primary_10_1080_07853890_2022_2082518 crossref_primary_10_14309_ajg_0000000000000596 crossref_primary_10_1177_17562848231167283 crossref_primary_10_1186_s12876_023_02769_5 crossref_primary_10_13105_wjma_v8_i2_163 crossref_primary_10_3748_wjg_v30_i1_50 crossref_primary_10_1016_j_cgh_2021_03_048 crossref_primary_10_12998_wjcc_v9_i2_334 crossref_primary_10_3390_jcm11206086 crossref_primary_10_1053_j_gastro_2020_12_031 crossref_primary_10_1016_j_cgh_2018_12_021 crossref_primary_10_1080_1744666X_2019_1593140 crossref_primary_10_1097_MEG_0000000000001731 crossref_primary_10_3390_biomedicines8070193 crossref_primary_10_1371_journal_pone_0223893 crossref_primary_10_15406_ghoa_2022_13_00494 crossref_primary_10_3748_wjg_v24_i33_3681 crossref_primary_10_3390_biomedicines11051408 crossref_primary_10_1016_j_heliyon_2023_e23439 crossref_primary_10_14309_ctg_0000000000000134 crossref_primary_10_1155_2018_5090849 crossref_primary_10_3390_jcm10102203 crossref_primary_10_1093_ecco_jcc_jjab182 crossref_primary_10_1111_cts_13575 crossref_primary_10_3164_jcbn_19_90 crossref_primary_10_3390_diagnostics10060367 crossref_primary_10_1371_journal_pone_0255012 crossref_primary_10_1080_00325481_2018_1503919 crossref_primary_10_1080_17474124_2023_2296564 crossref_primary_10_1097_MPG_0000000000002262 crossref_primary_10_1155_2019_3108025 |
Cites_doi | 10.1016/j.crohns.2011.09.008 10.1002/ibd.20312 10.1111/apt.12335 10.1038/nrgastro.2014.154 10.1053/j.gastro.2013.04.007 10.1097/00042737-200208000-00005 10.1016/0016-5085(90)90613-6 10.1186/1756-0500-2-221 10.1016/S0016-5107(04)01878-4 10.3748/wjg.v19.i45.8335 10.1038/ajg.2014.45 10.1097/MCG.0000000000000774 10.1097/MD.0000000000003477 10.3109/00365521.2012.660542 10.1097/MIB.0b013e3182810066 10.3109/00365521.2013.772230 10.1136/bmj.298.6666.82 10.1002/ibd.20986 10.15403/jgld.2014.1121.233.thv 10.1002/ibd.21838 10.1111/j.1572-0241.2007.01561.x 10.4318/tjg.2012.0421 10.1016/S0016-5085(76)80163-1 10.1097/MIB.0000000000001050 10.1136/gut.27.7.809 10.1002/bjs.6593 10.1111/j.1365-2036.2008.03835.x 10.1016/j.crohns.2013.09.016 10.1038/nature06005 10.1136/gut.2005.069476 10.1111/j.1365-2036.2010.04459.x 10.1016/j.cgh.2010.01.016 10.1111/jgh.12164 10.1002/ibd.21925 10.1007/s10350-007-0225-6 10.1007/s10620-016-4397-6 10.1097/MIB.0b013e31828a6551 10.1056/NEJM198712243172603 10.1016/j.crohns.2013.12.015 10.1038/ajg.2009.545 10.1177/2050640613501818 10.1053/j.gastro.2007.05.051 10.1097/MIB.0000000000000139 |
ContentType | Journal Article |
Copyright | The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. 2017 |
Copyright_xml | – notice: The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. 2017 |
DBID | 2RA 92L CQIGP ~WA NPM AAYXX CITATION 7X8 5PM |
DOI | 10.3748/wjg.v23.i46.8235 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库- 镜像站点 PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2219-2840 |
EndPage | 8247 |
ExternalDocumentID | 10_3748_wjg_v23_i46_8235 29290660 90888889504849555254484952 |
Genre | Journal Article |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 WFFXF XSB ~WA NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c506t-3d5ac2be9be1206b004f5f25d02230bfdfab131c81a3ebe7d5536b79a17502473 |
IEDL.DBID | RPM |
ISSN | 1007-9327 |
IngestDate | Fri Sep 01 02:33:39 EDT 2023 Fri Apr 12 08:55:27 EDT 2024 Fri Aug 23 00:26:54 EDT 2024 Sat Sep 28 08:50:01 EDT 2024 Wed Feb 14 10:07:48 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 46 |
Keywords | Fecal calprotectin Inflammatory bowel disease Disease activity Crohn’s disease Ulcerative colitis |
Language | English |
License | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c506t-3d5ac2be9be1206b004f5f25d02230bfdfab131c81a3ebe7d5536b79a17502473 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Correspondence to: Biao Nie, MD, PhD, Professor, Associate Chief Physician, Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, No. 614, West Huangpu Avenue, Guangzhou 510630, Guangdong Province, China. niebiao2@163.com Telephone: +86-15101503392 Fax: +86-20-38688025 Author contributions: Chen JM and Nie B designed the study and wrote the manuscript; Deng FH collected fecal and blood samples and completed patient case report; Liu T and Nie B performed all endoscopies and completed the endoscopic scoring sheet; Tong XD quantified fecal calprotectin; Gao S performed data analysis; all authors read and approved the final manuscript. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739930/ |
PMID | 29290660 |
PQID | 1983256199 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5739930 proquest_miscellaneous_1983256199 crossref_primary_10_3748_wjg_v23_i46_8235 pubmed_primary_29290660 chongqing_primary_90888889504849555254484952 |
PublicationCentury | 2000 |
PublicationDate | 2017-12-14 |
PublicationDateYYYYMMDD | 2017-12-14 |
PublicationDate_xml | – month: 12 year: 2017 text: 2017-12-14 day: 14 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2017 |
Publisher | Baishideng Publishing Group Inc |
Publisher_xml | – name: Baishideng Publishing Group Inc |
References | 23161295 - Turk J Gastroenterol. 2012;23(5):509-14 23669403 - Inflamm Bowel Dis. 2013 Aug;19(9):1839-45 16474109 - Gut. 2006 Mar;55(3):426-31 22069022 - Inflamm Bowel Dis. 2012 Sep;18(9):1634-40 3317057 - N Engl J Med. 1987 Dec 24;317(26):1625-9 18076736 - Am J Gastroenterol. 2008 Jan;103(1):154-61 2563951 - BMJ. 1989 Jan 14;298(6666):82-6 22398068 - J Crohns Colitis. 2012 May;6(4):412-8 19874614 - BMC Res Notes. 2009 Oct 29;2:221 3732890 - Gut. 1986 Jul;27(7):809-13 23432198 - J Gastroenterol Hepatol. 2013 Jul;28(7):1148-53 28426458 - Inflamm Bowel Dis. 2017 May;23 (5):791-797 25201042 - Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):583-4 24184171 - J Crohns Colitis. 2013 Dec;7(12):982-1018 24917985 - United European Gastroenterol J. 2013 Oct;1(5):368-74 23328771 - Inflamm Bowel Dis. 2013 Feb;19(2):332-41 23668698 - Aliment Pharmacol Ther. 2013 Jul;38(1):44-51 20139033 - Clin Gastroenterol Hepatol. 2010 Jul;8(7):591-9.e1; quiz e78-9 24418661 - J Crohns Colitis. 2014 Aug;8(8):789-95 23583432 - Gastroenterology. 2013 Jul;145(1):158-165.e2 15472670 - Gastrointest Endosc. 2004 Oct;60(4):505-12 19384912 - Br J Surg. 2009 Jun;96(6):663-74 19755969 - Am J Gastroenterol. 2010 Jan;105(1):162-9 17473939 - Dis Colon Rectum. 2007 Jun;50(6):861-9 21830282 - Inflamm Bowel Dis. 2012 Jun;18(6):1006-10 19462421 - Inflamm Bowel Dis. 2009 Dec;15(12):1851-8 27984399 - J Clin Gastroenterol. 2016 Dec 14;:null 22356594 - Scand J Gastroenterol. 2012 May;47(5):528-37 18022866 - Inflamm Bowel Dis. 2008 Jan;14(1):40-6 24642581 - Am J Gastroenterol. 2014 May;109(5):705-14 1248701 - Gastroenterology. 1976 Mar;70(3):439-44 24363525 - World J Gastroenterol. 2013 Dec 7;19(45):8335-41 23477356 - Scand J Gastroenterol. 2013 May;48(5):543-51 2394349 - Gastroenterology. 1990 Oct;99(4):956-63 27933473 - Dig Dis Sci. 2017 Feb;62(2):465-472 21039675 - Aliment Pharmacol Ther. 2010 Nov;32(9):1135-44 25267955 - J Gastrointestin Liver Dis. 2014 Sep;23(3):273-8 17681162 - Gastroenterology. 2007 Aug;133(2):412-22 18752630 - Aliment Pharmacol Ther. 2008 Nov 15;28(10):1221-9 27100452 - Medicine (Baltimore). 2016 Apr;95(16):e3477 25137415 - Inflamm Bowel Dis. 2014 Oct;20(10):1747-53 17653185 - Nature. 2007 Jul 26;448(7152):427-34 12172403 - Eur J Gastroenterol Hepatol. 2002 Aug;14(8):841-5 ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref39 ref16 ref38 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref42 ref41 ref22 ref21 ref43 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 |
References_xml | – ident: ref6 doi: 10.1016/j.crohns.2011.09.008 – ident: ref30 doi: 10.1002/ibd.20312 – ident: ref8 doi: 10.1111/apt.12335 – ident: ref27 doi: 10.1038/nrgastro.2014.154 – ident: ref3 doi: 10.1053/j.gastro.2013.04.007 – ident: ref26 doi: 10.1097/00042737-200208000-00005 – ident: ref18 doi: 10.1016/0016-5085(90)90613-6 – ident: ref31 doi: 10.1186/1756-0500-2-221 – ident: ref16 doi: 10.1016/S0016-5107(04)01878-4 – ident: ref25 doi: 10.3748/wjg.v19.i45.8335 – ident: ref28 doi: 10.1038/ajg.2014.45 – ident: ref41 doi: 10.1097/MCG.0000000000000774 – ident: ref14 doi: 10.1097/MD.0000000000003477 – ident: ref29 doi: 10.3109/00365521.2012.660542 – ident: ref34 doi: 10.1097/MIB.0b013e3182810066 – ident: ref9 doi: 10.3109/00365521.2013.772230 – ident: ref21 doi: 10.1136/bmj.298.6666.82 – ident: ref33 doi: 10.1002/ibd.20986 – ident: ref43 doi: 10.15403/jgld.2014.1121.233.thv – ident: ref11 doi: 10.1002/ibd.21838 – ident: ref2 doi: 10.1111/j.1572-0241.2007.01561.x – ident: ref35 doi: 10.4318/tjg.2012.0421 – ident: ref20 doi: 10.1016/S0016-5085(76)80163-1 – ident: ref42 doi: 10.1097/MIB.0000000000001050 – ident: ref23 doi: 10.1136/gut.27.7.809 – ident: ref37 doi: 10.1002/bjs.6593 – ident: ref32 doi: 10.1111/j.1365-2036.2008.03835.x – ident: ref12 doi: 10.1016/j.crohns.2013.09.016 – ident: ref1 doi: 10.1038/nature06005 – ident: ref22 doi: 10.1136/gut.2005.069476 – ident: ref24 doi: 10.1111/j.1365-2036.2010.04459.x – ident: ref40 doi: 10.1016/j.cgh.2010.01.016 – ident: ref5 doi: 10.1111/jgh.12164 – ident: ref7 doi: 10.1002/ibd.21925 – ident: ref36 doi: 10.1007/s10350-007-0225-6 – ident: ref15 doi: 10.1007/s10620-016-4397-6 – ident: ref4 doi: 10.1097/MIB.0b013e31828a6551 – ident: ref19 doi: 10.1056/NEJM198712243172603 – ident: ref38 doi: 10.1016/j.crohns.2013.12.015 – ident: ref17 doi: 10.1038/ajg.2009.545 – ident: ref39 doi: 10.1177/2050640613501818 – ident: ref10 doi: 10.1053/j.gastro.2007.05.051 – ident: ref13 doi: 10.1097/MIB.0000000000000139 |
SSID | ssj0023352 |
Score | 2.4458706 |
Snippet | AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal... To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD). Fecal calprotectin (FC),... AIMTo optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD).METHODSFecal calprotectin... |
SourceID | pubmedcentral proquest crossref pubmed chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 8235 |
SubjectTerms | Prospective Study |
Title | Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China |
URI | http://lib.cqvip.com/qk/84123X/201746/90888889504849555254484952.html https://www.ncbi.nlm.nih.gov/pubmed/29290660 https://search.proquest.com/docview/1983256199 https://pubmed.ncbi.nlm.nih.gov/PMC5739930 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwEB0Bl3KpqCgQoJUr9VKpycZ2HK-5IQRClah6KBK3yPbadCs2C-wC4u-Z8SbbLr01p0SxI8dv7Bl7Zp4BPkcXFKr5SJFqKq-GPOYmVDIPJiivvZU2eXQvvtfnl9W3K3W1BqrPhUlB-96Ni_ZmUrTjXym28nbiB32c2ODHxYnSpFbLwTqsayn7JXq3yqIkouTiLHWOxole-CaJZWXw9Pu6eBSyGFd1MRSSTq0RhvjOiaDyDU437fUdKoxVFfWP3fk6fPIvfXS2BW87Q5IdLxr8DtZCuw2zU2KEsP6ZTSNraaf10VJ8OvtD6j1j45ZN0kimLT18iigUk-RsZ276FG5Y57RhlPNAR0scsWOG7euTMlmipKXPpMO338Pl2enPk_O8O1Yh96qs57kcKeuFC8YFLsqaxm1UUagRqnNZujiK1nHJ_ZBbiRDrkVKydtpYtDRQo2u5Axv4B2EPWKisJaMtameqGqsMubc4bUnsVu55mcHXZa82twv6jIYiq_AyCicPXJ4pRSxpdCcy-NJ3_LI0LlIIuwaxaxC7BrFrCLsMPvXINDgiyM1h2zB9mDXc4CyFZqExGewukFp-rYc7A72C4bIAsW2vvkEhTKzbndDt_3fNA9gUZBNwkfPqEDbm9w_hA1o0c_cxSfAL4u32Uw |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcigXHuKV8jISFySSje04WXOrqlYLdCsOLeotsr12u9DNtuxuK_j1zDibhS0nyClR7EjWfJ75nBl_BngTrFcY5gNVqqm06POQal_I1GuvXOWMNDGjOzwsB8fFxxN1sgGq2wsTi_adHWfN-SRrxmextvJi4npdnVjv83BXVRRW894tuI3zVahukb5cZ9E2opjkzKsU6UnVZidJZ6V3_fU0uxIyGxdl1heSzq0RmhTPSaJyCx1Oc3qJIWM9SP3FPG8WUP4RkfbvwZduLG0hyrdsMbeZ-3lD5vGfB3sf7i45KttpXz-ADd88hNkeiU0Y94NNA2voJ-6VodJ39lsvfMbGDZtEJ0F_C_EpIN4mMY_P7PTan7NlPojRdgo6teI922E4gG6_J4tqt_SZeK73Izje3zvaHaTLExtSp_JynsqRMk5Yr63nIi_JJQQVhBohU5C5DaNgLJfc9bmRiJ5qpJQsbaUNkhgkC5V8DJs4Av8UmC-MIT4YKquLErv0uTPoESXaizueJ_BuZa76olXmqKloCy-t0C_hyk8pEmCjO5HA286iq9a4_iFQ1AiKGkFRIyhqAkUCrzuT1zjZKINiGj9dzGqu0QEi49Q6gSctBFZf63CUQLUGjlUDEvJef4Mmj4LeSxNv_3fPV7A1OBoe1AcfDj89gzuCqAcXKS-ew-b8-8K_QOI0ty_jNPkF_BEYXA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMCFh4ASnkbigkQetuN4za0qXZVHqx6oVHGJbMcuS7vZLbvbCn49M85m6ZZbc9ponUjWfJ75nBl_Q8jbYL2EMB-wUk2m5YCFVPtSpF576ZQzwsSM7t5-tXtYfj6SR5dafcWifWdHWXs6ztrRj1hbOR27vK8Tyw_2tqXCsFrk0ybkN8ktWLNc9Rv15V4LjxLFRGehUqAoqstQotZKfvHzODvnIhuVVTbgAnvXcI2q5yhTeQecTnt8BmFjPVD9xz6vFlFeikrD--R7P5-uGOUkW8xt5v5ckXq81oQfkHtLrkq3uiEPyQ3fPiKzHRSdMO43nQTa4sfcc4Ml8PSfbviMjlo6js4CvxrCXQDcjWM-n9rJhT-ly7wQxWMV2L3iA92iMIn-3CeNqrf4mtjf-zE5HO58295Nl50bUieLap6KRhrHrdfWM15U6BqCDFw2wBhEYUMTjGWCuQEzAlCkGilFZZU2QGaANCjxhGzADPxTQn1pDPLCoKwuK3hkwJwBzyjAZsyxIiHvVyarp51CR43FW3BpCf4JdoBSohAb_uIJeddbdTUa9kEIjBqAUQMwagBGjcBIyJve7DUsOsykmNZPFrOaaXCEwDy1TshmB4PV23osJUStAWQ1AAW91_8Bs0dh76WZn137ydfk9sHHYf310_6X5-QuRwbCeMrKF2Rj_mvhXwJ_mttXcaX8Bb5wGtw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+noninvasive+evaluations+in+monitoring+inflammatory+bowel+disease+activity%3A+A+prospective+study+in+China&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Chen%2C+Jin-Min&rft.au=Liu%2C+Tao&rft.au=Gao%2C+Shan&rft.au=Tong%2C+Xu-Dong&rft.date=2017-12-14&rft.issn=1007-9327&rft.volume=23&rft.issue=46&rft.spage=8235&rft.epage=8247&rft_id=info:doi/10.3748%2Fwjg.v23.i46.8235&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v23_i46_8235 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |